Contagious Bovine Pleuropneumonia

Contagious bovine pleuropneumonia is a severe, highly contagious respiratory disease of cattle caused by Mycoplasma mycoides subspecies mycoides, representing one of the most devastating transboundary animal diseases affecting the global cattle industry. This disease is characterized by fibrinous pleuropneumonia that causes significant morbidity and mortality in affected herds, with case fatality rates potentially reaching fifty percent or higher in naive populations. CBPP is classified as a notifiable disease by the World Organisation for Animal Health and is subject to strict international trade restrictions, making it not only a health concern but also a major barrier to international livestock trade for affected countries. Understanding this disease is critical for veterinarians, livestock producers, and regulatory authorities worldwide.

The current geographic distribution of contagious bovine pleuropneumonia is primarily concentrated in sub-Saharan Africa, where the disease remains endemic in many countries and continues to cause substantial economic losses. Historical outbreaks have occurred on every continent with cattle populations, though aggressive eradication campaigns eliminated the disease from North America, Australia, Europe, and most of Asia during the nineteenth and twentieth centuries. Sporadic incursions continue to threaten CBPP-free regions, necessitating ongoing surveillance and rapid response capabilities. In endemic areas, the disease affects both traditional pastoral systems and more intensive cattle production, with prevalence varying based on cattle movements, vaccination coverage, and surveillance intensity.

The economic and social impacts of contagious bovine pleuropneumonia are profound in affected regions and create significant concerns for disease-free areas. Direct losses from mortality, morbidity, and reduced productivity devastate individual producers and communities dependent on cattle for livelihoods. Indirect costs including trade restrictions, surveillance expenses, and vaccination programs add substantially to the burden. Countries affected by CBPP face barriers to accessing international livestock and beef markets, limiting economic development opportunities. For CBPP-free countries, the constant threat of introduction requires sustained investment in border controls, surveillance, and emergency response preparedness. These multifaceted impacts make CBPP a priority for national and international animal health authorities.

Detection, reporting, and control of contagious bovine pleuropneumonia require coordinated efforts between livestock producers, veterinary services, and regulatory authorities. The disease's highly contagious nature and potential for rapid spread demand immediate response when suspected cases are identified. Veterinarians encountering cattle with compatible clinical signs must consider CBPP in differential diagnosis, particularly when disease history includes potential exposure to endemic areas. Laboratory confirmation through official channels triggers regulatory response protocols. In endemic regions, vaccination combined with movement control and surveillance forms the basis of control programs. In free regions, stamping out policies with compensation programs enable rapid elimination of introduced disease.

The causative agent of contagious bovine pleuropneumonia is Mycoplasma mycoides subspecies mycoides, specifically the small colony type, a unique bacterial pathogen exquisitely adapted to cattle. This organism belongs to the Mollicutes class, characterized by absence of a cell wall and extremely small genome, making it dependent on host tissues for many nutrients and metabolic functions. The small colony type designation differentiates it from the large colony type, which causes different disease syndromes. Mmm produces various virulence factors enabling respiratory colonization, immune evasion, and tissue damage. Genetic variation between strains influences virulence and potentially vaccine effectiveness. The organism's fragility outside the host limits environmental persistence but its efficiency in direct transmission ensures maintenance in cattle populations.

No genetic breed predisposition to CBPP infection has been definitively established, as virtually all cattle are susceptible to infection with Mycoplasma mycoides subspecies mycoides when exposed. However, some evidence suggests variation in disease severity among different cattle populations, potentially reflecting differences in immune response characteristics. Bos indicus breeds common in tropical endemic areas may show different disease patterns compared to Bos taurus breeds. Indigenous African cattle populations with long exposure history may demonstrate partial resistance compared to exotic breeds introduced to endemic areas. These observations suggest complex interactions between host genetics, exposure history, and acquired immunity rather than true genetic resistance.

Environmental conditions influence CBPP transmission dynamics and outbreak patterns. The organism survives poorly in the environment, with viability outside the host limited to days under favorable conditions and much shorter under adverse conditions. Direct animal-to-animal transmission through respiratory droplets is the primary route, favored by close contact and confined conditions. Dry, dusty conditions may enhance aerosol transmission over short distances. Cool temperatures may prolong organism survival in expelled respiratory secretions. Seasonal patterns in endemic areas often correlate with dry season congregation of cattle at limited water and grazing resources. Understanding these environmental influences informs surveillance and control timing.

Multiple risk factors influence the likelihood of CBPP introduction and spread within cattle populations. Movement of infected animals represents the primary risk for disease spread to new areas, whether through formal trade channels or informal cross-border movements. Introduction of cattle from endemic regions into naive populations creates high-risk scenarios. Congregation of cattle at markets, watering points, or shared grazing increases transmission opportunities. Inadequate surveillance failing to detect early cases allows establishment before control responses. Insufficient vaccination coverage in endemic areas maintains disease circulation. Wildlife reservoirs play minimal role, as the disease is maintained primarily in cattle populations, though buffalo may occasionally be involved.

The pathophysiology of contagious bovine pleuropneumonia involves progressive pulmonary infection with characteristic pleuropneumonia development. Initial colonization occurs in the upper respiratory tract following inhalation of organism-laden droplets from infected cattle. Organisms descend to the lower respiratory tract where multiplication stimulates intense inflammatory responses. Fibrinous exudation into alveoli and pleural space produces the characteristic marbled lung appearance. Thickened interlobular septa and pleural adhesions develop as disease progresses. Some animals develop chronic lesions called sequestra, encapsulated necrotic lung tissue that may harbor viable organisms for extended periods. These sequestra-bearing carriers pose particular challenges for disease control as they may shed organisms intermittently.

Early warning signs of contagious bovine pleuropneumonia may be subtle, particularly in the initial stages of an outbreak or in chronic cases. Mild fever elevation may be the only initial finding in some affected cattle, easily overlooked without systematic monitoring. Slight decrease in feed intake and milk production in dairy cattle may precede obvious respiratory signs. Mild coughing, sometimes only apparent after exertion, develops as lower respiratory infection establishes. Cattle may show subtle changes in behavior including reduced activity and reluctance to move. These early signs provide opportunity for detection before severe disease develops, emphasizing the importance of vigilant observation in at-risk situations.

Classic clinical symptoms of acute CBPP reflect severe pleuropneumonia with systemic illness. High fever, typically 104 to 107 degrees Fahrenheit, persists throughout the acute disease phase. Rapid, shallow, labored breathing with obvious respiratory distress characterizes pulmonary involvement. Cattle stand with elbows abducted, head and neck extended, and back arched to ease breathing. Dry, painful cough develops early, becoming moist as disease progresses. Grunting expiration reflects pleural pain associated with fibrinous pleuritis. Nasal discharge may be serous initially, progressing to mucopurulent. Drooling and grinding of teeth indicate pain and general distress. These dramatic signs in acute cases facilitate clinical recognition.

Behavioral changes in cattle with CBPP reflect respiratory compromise, pain, and systemic illness. Affected cattle become depressed, standing apart from the herd with dull expression. Reluctance to move even when encouraged reflects both weakness and respiratory limitation. Decreased or absent rumination indicates general systemic illness. Cattle may assume sternal recumbency with reluctance to rise when approached. Reduced water and feed intake leads to rapid weight loss. Pregnant cattle may abort due to fever and systemic stress. These behavioral indicators often prompt investigation that identifies respiratory disease.

Physical examination findings reveal characteristic abnormalities indicative of pleuropneumonia. Elevated rectal temperature during acute disease, typically between 104 and 107 degrees Fahrenheit, reflects active infection. Marked increase in respiratory rate, often exceeding 50 breaths per minute, with labored effort indicates severe pulmonary compromise. Percussion of the thorax reveals areas of dullness corresponding to consolidated lung and pleural effusion. Auscultation identifies absence of normal lung sounds over affected areas with possible friction rubs early and fluid sounds later. Prominent jugular pulse may be visible from right heart strain. Weight loss develops rapidly due to reduced intake and metabolic demands of severe illness.

Symptom progression in CBPP follows a variable course depending on infection severity and host factors. Peracute cases may die within days of symptom onset with overwhelming infection. Acute cases progress over one to three weeks with severe respiratory signs and high mortality without treatment. Subacute cases develop more gradually with less severe signs but prolonged illness. Chronic cases may show intermittent mild respiratory signs with persistent weight loss and reduced productivity. Some cattle recover clinically while retaining lung sequestra that harbor organisms. Understanding these variable presentations aids clinical recognition across the disease spectrum.

Severe symptoms indicating critical disease requiring immediate action include signs of respiratory failure or systemic decompensation. Extreme respiratory distress with open-mouth breathing and cyanosis of mucous membranes indicates imminent respiratory failure. Collapse or recumbency with inability to rise suggests cardiovascular collapse. Subnormal temperature following high fever indicates circulatory failure. Subcutaneous emphysema from ruptured lungs may develop in severe cases. Any cattle displaying these critical signs have grave prognosis even with intensive intervention. Immediate isolation and veterinary notification are essential, with CBPP considered in differential diagnosis where geographically relevant.

Clinical examination provides initial indication of possible CBPP requiring laboratory confirmation. Veterinary assessment evaluates respiratory parameters including rate, character, and distribution of abnormal sounds. Percussion and auscultation localize pulmonary involvement and detect pleural effusion. Assessment of overall clinical status indicates disease severity and prognosis. Critical evaluation of history including geographic origin, recent movements, and contact with potentially infected cattle informs risk assessment. Any compatible clinical picture in cattle from endemic areas or with relevant exposure history must be considered presumptive CBPP pending laboratory confirmation. Immediate notification of regulatory authorities is required when CBPP is suspected.

Diagnostic testing for CBPP utilizes multiple laboratory methods for detection and confirmation. Isolation of Mycoplasma mycoides subspecies mycoides from respiratory samples or lung tissue provides definitive diagnosis but requires specialized laboratory capabilities. PCR testing enables rapid, specific detection of organism DNA from clinical samples including nasal swabs and lung tissue. Complement fixation testing detects antibodies to Mmm and remains the prescribed test for international trade. Competitive ELISA provides an alternative serological method with practical advantages for screening programs. Immunohistochemistry can identify organisms in tissue sections. Postmortem examination with gross and histopathological evaluation reveals characteristic lesions supporting diagnosis. Official diagnostic laboratories with appropriate containment handle CBPP samples.

Differential diagnosis must distinguish CBPP from other causes of respiratory disease in cattle. Bovine respiratory disease complex including Mannheimia haemolytica pneumonia produces similar clinical signs. Tuberculosis may produce chronic respiratory disease with some similar features. Pasteurellosis causes acute pneumonia requiring differentiation. Traumatic reticulopericarditis produces respiratory distress from different etiology. East Coast fever in endemic areas may cause respiratory signs among other symptoms. Heartwater in tick-endemic areas produces respiratory involvement. Accurate differentiation requires laboratory testing, particularly in areas where CBPP has not been previously recognized. All severe respiratory disease outbreaks should prompt consideration of CBPP as part of foreign animal disease awareness.

Surveillance and population-level diagnostic approaches support CBPP control programs in endemic areas and early detection in free regions. Abattoir surveillance examining lungs at slaughter identifies characteristic lesions indicating infection. Serological surveys using complement fixation or ELISA measure population exposure and immunity levels. Active surveillance in high-risk areas or following contact with known outbreaks enables early detection. Tracing of animal movements from known infected premises identifies potentially exposed herds for testing. International cooperation in surveillance near endemic regions supports early warning systems. These systematic approaches enable both endemic area management and protection of disease-free regions.

Treatment of contagious bovine pleuropneumonia is a highly regulated matter subject to national and international guidelines that vary by country and disease status. In countries free of CBPP, treatment is generally prohibited, with stamping out through slaughter of infected and exposed animals being the standard response to maintain disease-free status. This approach, combined with cleaning and disinfection, prevents establishment of the disease. In endemic countries, treatment policies vary based on available resources, prevalence, and control program strategies. Some programs prohibit treatment to reduce carrier development, while others permit treatment in certain circumstances. Any treatment decisions must be made in coordination with veterinary and regulatory authorities.

Where treatment is permitted in endemic situations, antimicrobial therapy can reduce clinical signs and mortality in affected cattle. Mycoplasma mycoides subspecies mycoides, lacking a cell wall, is inherently resistant to beta-lactam antibiotics. Macrolides including tylosin and tilmicosin demonstrate activity against the organism. Tetracyclines, particularly long-acting oxytetracycline, provide an alternative treatment option. Fluoroquinolones show good activity where approved for use in cattle. Treatment typically requires extended courses due to the organism's intracellular location and chronic nature of lesions. However, treatment does not eliminate infection and treated cattle may become chronic carriers harboring sequestra. This carrier potential is a primary reason why many control programs prohibit treatment.

Supportive care for cattle with CBPP focuses on maintaining hydration and comfort during illness. Fluid therapy addresses dehydration from fever and reduced water intake. Anti-inflammatory drugs may provide symptomatic relief, though use must consider regulatory status. Protection from environmental stressors including temperature extremes and inclement weather reduces additional burden on compromised cattle. Provision of palatable, easily consumed feed encourages nutritional intake. These supportive measures may improve survival in treated cattle but cannot address underlying infection. The decision to provide supportive care must consider regulatory requirements and program objectives.

Vaccination plays a central role in CBPP control in endemic regions where eradication is not immediately achievable. Live attenuated vaccines based on the T1/44 strain are most widely used, providing protection lasting approximately one year. Vaccine is administered subcutaneously, with reactions at the injection site common and expected. Mass vaccination campaigns aim to achieve high population coverage to reduce transmission and clinical disease. Ring vaccination around outbreaks may be employed in some control strategies. Vaccine effectiveness depends on proper cold chain maintenance and administration technique. Improved vaccines with better efficacy and fewer reactions remain a research priority. Vaccination programs typically operate in coordination with movement controls and surveillance.

Regulatory control measures form the primary response to CBPP in most situations, superseding individual animal treatment considerations. Immediate quarantine of affected premises prevents further disease spread. Stamping out through slaughter of infected and exposed cattle eliminates infection sources in eradication programs. Cleaning and disinfection of premises reduces environmental contamination. Movement restrictions prevent spread beyond affected areas. Contact tracing identifies potentially exposed herds for testing and observation. Compensation programs facilitate cooperation with control measures. International notification through OIE triggers trade restrictions protecting other countries. These regulatory responses prioritize population-level control over individual animal outcomes.

Decision making regarding CBPP response involves multiple stakeholders including producers, veterinary services, and regulatory authorities. The choice between treatment, vaccination, and stamping out depends on disease status, program objectives, and available resources. In countries with endemic disease, gradual progress toward control may employ vaccination and restricted treatment. In disease-free countries or zones, immediate eradication through stamping out protects disease-free status and trade access. Producer compensation for destroyed animals facilitates cooperation with control measures. The high stakes of CBPP control require coordinated decision making with clear authority and communication.

Recovery from contagious bovine pleuropneumonia, where cattle are treated rather than culled, follows a prolonged and often incomplete course. Cattle that survive acute disease may require weeks to months before clinical stabilization, with fever resolution and respiratory improvement occurring gradually. Weight recovery is slow due to permanent lung damage and ongoing metabolic demands of tissue repair. Full respiratory function rarely returns following significant pulmonary involvement, with affected cattle showing reduced exercise tolerance permanently. The timeline from acute disease through apparent clinical recovery typically spans two to three months minimum, with some cattle showing ongoing signs for much longer.

Post-recovery monitoring of treated cattle must account for the possibility of chronic carrier status. Cattle that recover clinically may harbor lung sequestra containing viable Mycoplasma mycoides subspecies mycoides. These carriers appear healthy but may shed organisms intermittently, particularly during stress. Serological testing may remain positive for extended periods following infection. Clinical observation for recurrence of respiratory signs identifies cattle experiencing disease reactivation. The uncertainty regarding carrier status of recovered cattle is a primary reason why treatment is discouraged or prohibited in most control programs. Recovered cattle pose ongoing risks to naive populations.

Prognosis for cattle affected by CBPP varies based on disease severity and individual response. Mortality rates in naive populations experiencing acute disease may reach fifty percent or higher without intervention. Cattle with early-stage disease have better survival prospects than those with advanced pulmonary involvement. Young cattle and calves may experience higher mortality rates than adults in some outbreaks. Cattle that survive acute disease face permanent respiratory impairment affecting productivity. The possibility of carrier status means that even recovered cattle pose epidemiological concerns. Overall prognosis must consider not only individual survival but implications for herd and population health.

Return to production for recovered cattle involves significant limitations and concerns. Respiratory capacity reduction limits tolerance for heat, exertion, and other stressors. Productivity including milk production and weight gain typically remains impaired. Breeding cattle may show reduced fertility and conception rates. Chronic carriers pose transmission risks if introduced to naive populations. In endemic areas, recovered cattle contribute to population immunity but also to ongoing disease maintenance. In areas implementing eradication, recovered cattle generally cannot be retained due to carrier risks. These factors severely limit the productive future of cattle recovering from CBPP.

Vaccination provides the primary preventive tool against CBPP in endemic regions where disease persists. The T1/44 live attenuated vaccine is most widely used, derived from a naturally attenuated strain. Vaccine is administered subcutaneously, typically in the tail base, with local reactions expected and indicating immune response. Annual revaccination maintains immunity, as protection wanes over twelve to eighteen months. Mass vaccination campaigns targeting high coverage rates reduce population susceptibility and transmission. Quality control ensuring proper vaccine handling and cold chain maintenance is essential for effectiveness. Improved vaccines with better protection, fewer reactions, and longer duration remain research priorities. Vaccination programs operate within broader control strategies including surveillance and movement management.

Biosecurity and movement control represent critical prevention elements for both endemic and free regions. In endemic areas, restricting cattle movements reduces spread between herds and regions. Quarantine of introduced cattle before mixing with resident herds allows observation for disease development. Market surveillance and restrictions during outbreak periods limit transmission at congregation points. In disease-free regions, import controls prevent introduction through international cattle trade. Testing and quarantine requirements for cattle from affected regions provide additional protection. Border controls along boundaries with endemic areas prevent illegal introductions. These movement-based measures are essential complements to vaccination and surveillance.

Surveillance programs enable early detection essential for effective CBPP control. Clinical surveillance by farmers and veterinarians identifies suspect cases for investigation. Abattoir inspection examining lungs for characteristic lesions detects infection in slaughter cattle. Serological surveys measure population exposure and immunity levels. Active surveillance targeting high-risk populations or areas intensifies detection efforts. Participatory epidemiology engaging livestock keepers improves disease reporting in pastoral systems. International intelligence sharing provides early warning of disease in neighboring regions. Effective surveillance enables rapid response before widespread establishment occurs.

International cooperation supports global CBPP control through coordinated efforts and shared resources. The World Organisation for Animal Health maintains the official list of CBPP-affected countries and sets diagnostic standards. The Food and Agriculture Organization provides technical assistance for control programs in endemic countries. International trade regulations create incentives for disease control by restricting market access for affected countries. Regional coordination mechanisms address transboundary disease challenges. Research partnerships develop improved diagnostics and vaccines. Financial support from international organizations and donor countries enables control programs where resources are limited. This global framework supports progress toward CBPP control and eventual eradication.

Eradication strategies aim to eliminate CBPP from affected regions through systematic application of control measures. Combination of vaccination, movement control, surveillance, and stamping out progressively reduces prevalence. Zoning establishes disease-free areas that can be expanded as control succeeds. Final elimination phase intensifies surveillance and may eliminate vaccination to enable definitive freedom demonstration. Post-eradication surveillance maintains vigilance against reintroduction. Historical successes in Europe, North America, and Australia demonstrate feasibility of eradication. Current programs in Africa face challenges from resource limitations, porous borders, and complex pastoral systems. Sustained commitment and international support are required for ultimate global eradication.

Daily management and monitoring practices in CBPP-endemic areas emphasize early disease detection and reporting. Routine observation of cattle during normal husbandry activities identifies animals showing respiratory signs. Fever detection through observation of behavior changes or systematic temperature monitoring catches early cases. Monitoring of production parameters including milk yield and body condition reveals declining performance suggesting illness. Mortality tracking with investigation of deaths provides disease surveillance data. Reporting of suspect cases to veterinary authorities enables rapid response. Training of livestock keepers in disease recognition improves surveillance sensitivity. These daily practices form the foundation of community-based disease awareness.

Housing and herd management practices influence CBPP transmission risk. Reducing congregation of cattle from different sources limits exposure opportunities. Separation of sick animals from healthy cattle reduces within-herd transmission. Quarantine of newly acquired animals before mixing with resident herds allows observation for disease development. Avoiding shared water points and grazing with potentially infected herds during outbreak periods reduces exposure. Reducing stress factors that may compromise immunity supports disease resistance. These management practices complement vaccination in endemic area control strategies.

Herd health programs in endemic areas integrate vaccination with surveillance and management practices. Vaccination scheduling ensures coverage before high-risk periods such as dry season congregation. Booster protocols maintain immunity throughout the year. Record keeping documents vaccination status of individual animals and herds. Coordination with veterinary services ensures access to quality vaccine and technical support. Monitoring of vaccine reactions and adverse events supports program safety. Integration with other disease control activities maximizes efficiency of veterinary service delivery. Comprehensive programs achieve better control than individual interventions applied in isolation.

Record keeping and documentation support CBPP control programs at individual and population levels. Animal identification enables tracking of vaccination status and health history. Movement records document origins and destinations supporting contact tracing. Health event recording including suspect cases and confirmed diagnoses provides surveillance data. Vaccination records verify coverage and identify gaps requiring attention. Mortality records with cause of death documentation support epidemiological analysis. These records serve both individual herd management and broader program evaluation needs.

Economic considerations profoundly influence CBPP prevention and control at all levels. Individual producers weigh vaccination costs against disease risks and potential losses. National programs require sustained funding for vaccine procurement, delivery systems, and surveillance. Compensation programs for cattle destroyed during control operations require significant resources. Trade benefits from disease-free status provide economic incentives for control investment. Cost-benefit analyses inform policy decisions regarding control strategy intensity. International support may be essential for resource-limited countries to implement effective programs. Sustainable financing mechanisms are essential for long-term control progress.

All cattle breeds are considered susceptible to contagious bovine pleuropneumonia, with no documented true genetic resistance to Mycoplasma mycoides subspecies mycoides infection. However, observations suggest possible variation in disease expression among different cattle populations. Indigenous African cattle breeds with long histories of exposure to endemic CBPP may demonstrate some degree of tolerance or resistance compared to exotic breeds. Bos indicus cattle common in tropical regions may differ from Bos taurus breeds in disease manifestation. Calves and young cattle may experience higher mortality rates than adults in some outbreak situations. These observations likely reflect complex interactions of genetics, exposure history, and acquired immunity rather than simple breed-based resistance.

Production system characteristics influence CBPP risk beyond breed considerations. Pastoral and transhumant systems with extensive cattle movements face higher transmission risk. Traditional systems where cattle from multiple owners share grazing and water resources increase exposure opportunities. Intensive systems with purchased cattle introduction face introduction risks. Dairy operations with introduced genetics may bring susceptible animals into endemic areas. Communal grazing arrangements complicate movement control and contact tracing. Understanding these system-specific factors guides targeted control strategies. Production system modification may reduce disease risk regardless of breed composition.

Genetic approaches to CBPP control remain limited, with no practical breeding strategies currently available. Research has explored genetic markers associated with immune response and disease resistance. Studies comparing different cattle populations have identified some variation in susceptibility. However, practical genetic selection for CBPP resistance has not been developed. Cross-breeding programs incorporating potentially more resistant genetics face practical and economic constraints. Currently, vaccination and management-based approaches remain the primary control tools. Future research may identify opportunities for genetic improvement as an additional component of integrated control strategies.

Several conditions may co-occur with or complicate contagious bovine pleuropneumonia in affected cattle. Secondary bacterial infections may develop in lungs already compromised by CBPP. Parasitic infections common in endemic tropical areas may affect overall health and disease response. Nutritional deficiencies prevalent in pastoral systems may compromise immune function. Concurrent tick-borne diseases in tick-endemic areas add to disease burden. Stress from drought, inadequate nutrition, and long-distance movement may trigger disease in carriers. Comprehensive health management must address these multiple challenges facing cattle in CBPP-endemic regions.

Conditions presenting similar clinical signs to CBPP require careful differentiation for accurate diagnosis. Bovine respiratory disease complex from various bacterial pathogens produces similar respiratory signs. Tuberculosis causes chronic respiratory disease with some overlapping features. Acute pasteurellosis may resemble peracute CBPP. Traumatic reticulopericarditis produces respiratory distress from different etiology. East Coast fever in endemic areas includes respiratory involvement among systemic signs. Heartwater may cause respiratory signs in susceptible cattle. Laboratory diagnosis is essential for definitive differentiation, particularly where CBPP has not been previously recognized.

Complications and sequelae of CBPP significantly impact surviving cattle. Chronic lung sequestra containing viable organisms create carrier status. Permanent lung damage from extensive consolidation reduces respiratory capacity. Pleural adhesions restrict lung expansion and may cause chronic pain. Right heart failure may develop secondary to chronic pulmonary disease. Reduced productivity persists indefinitely in recovered animals. Chronic carriers pose ongoing transmission risks to susceptible cattle. These long-term consequences emphasize the importance of prevention over treatment and the challenges of living with endemic CBPP.